Case management of patients with Type 2 diabetes mellitus: a cross-sectional survey in Chongqing, China.

Journal Article

Type 2 diabetes mellitus has been identified as one of the priority diseases and included in the essential public health service package in China. This study investigated the frequency of follow-up visits and contents of care for case management of patients with Type 2 diabetes in Chongqing located in the western China, in terms of the regional practice guideline; and analyzed factors associated with the use of care.A cross-sectional survey was conducted with patients diagnosed with Type 2 diabetes in two areas in Chongqing. Total 502 participants (out of 664 people eligible) completed the interview. The outcome measures included at least four follow-up visits in a year, annual HbA1c test, blood lipid test and diabetic screening for nephropathy and eyes. Logistic regression analysis was applied to examine the association between participants' demographic and socio-economic characteristics and outcome measures.Over the one-year study period, 65% of participants had four or more follow-up visits. In light of the recommended tests, the proportions of having HbA1c test, blood lipid test and screening for nephropathy and eyes annually were 8, 54, 45 and 44%, respectively. After adjusting for study sites, age, sex, education, type of residence, level of income, the patients who were covered by Urban Employee Basic Medical Insurance, were enrolled in the targeted disease reimbursement program, and lived with diabetes more than five years were more likely to have regular follow-up visits and the recommended tests.Case management for patients with Type 2 diabetes mellitus was not effectively implemented in terms of frequency of follow-up visits and recommended tests over one-year period, as indicated in the regional practice guideline.

Full Text

Duke Authors

Cited Authors

  • He, M; Gao, J; Liu, W; Tang, X; Tang, S; Long, Q

Published Date

  • February 11, 2017

Published In

Volume / Issue

  • 17 / 1

Start / End Page

  • 129 -

PubMed ID

  • 28187724

Electronic International Standard Serial Number (EISSN)

  • 1472-6963

International Standard Serial Number (ISSN)

  • 1472-6963

Digital Object Identifier (DOI)

  • 10.1186/s12913-017-2039-0

Language

  • eng